|Bid||334.25 x 900|
|Ask||334.95 x 800|
|Day's Range||331.66 - 336.29|
|52 Week Range||220.05 - 345.50|
|Beta (3Y Monthly)||1.35|
|PE Ratio (TTM)||11.15|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Unlike most biotech IPOs, 10X Genomics already has nine-figure revenue, and CEO Serge Saxonov says thee's more to come.
10X Genomics is one of the hottest life sciences companies, hitting the market today after an expected $448.5 million IPO. But Bio-Rad Laboratories claims 10X's products are based on patents it holds.
Biome's working capital fell 37% to CA$1,324,582 in the second quarter. Biome's first licensed producer under Canada's Cannabis Act, Highland Grow, reported standalone net profitability in its second commercial production quarter. Biome was approved for selling cannabis in Saskatchewan, while adding Manitoba to its national supply footprint.
This company has helped fuel the revolution in single-cell sequencing, which has accelerated discoveries in cancer, immunology and neuroscience.
NetApp Inc. this year paid its median employee just shy of $200,000 — a level that puts it on par with some of Silicon Valley's biggest companies and represents a 26 percent jump, year-over-year.
Bio-Rad (BIO) delivered earnings and revenue surprises of 12.95% and 1.66%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In-vitro Diagnostics has successfully proven itself to be the best diagnostic procedures. So, investors can add stocks from this space to their watchlist.
Facebook makes more profit per employee than any other tech company on the Fortune 500: A whopping $634,694 per year. Here's how that compares with other major tech employers like Google, Apple and Cisco.
Luminex (LMNX) submits the ARIES MRSA assay to the FDA for clearance. The company's ARIES system will get a substantial boost once the FDA clearance is through.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Bio-Rad Laboratories, Inc. New York, July 01, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Bio-Rad Laboratories, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Moody's Investors Service ("Moody's") upgraded the unsecured rating of Bio-Rad Laboratories, Inc. ("Bio-Rad") to Baa2 from Baa3. The upgrade reflects the recent improvement in Bio-Rad's operating performance, including solid profit margin expansion, and progress made in its multi-year ERP implementation. The upgrade also reflects the company's consistently strong credit metrics.
Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter. Trends reversed 180 degrees during the first quarter amid Powell's pivot and optimistic expectations towards a trade deal with China. Hedge funds and institutional investors tracked by Insider Monkey usually invest a disproportionate amount of their […]
The big shareholder groups in BIOTON S.A. (WSE:BIO) have power over the company. Institutions will often hold stock in...
Large Bay Area tech employers that pay a typical employee more than $200,000 per year include the typical suspects like Google parent Alphabet Inc., Facebook and Netflix. But several companies that are lesser-known outside Silicon Valley also pay top dollar for talent.
Bio Rad Laboratories Inc NYSE:BIOView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for BIO with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BIO. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $298 million over the last one-month into ETFs that hold BIO are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.